Dechra Pharmaceuticals PLC Appointment of John Shipsey as Non-Executive (7891L)
18 May 2022 - 4:06AM
UK Regulatory
TIDMDPH
RNS Number : 7891L
Dechra Pharmaceuticals PLC
17 May 2022
17 May 2022
Dechra(R) Pharmaceuticals PLC
(Dechra, the Company or the Group)
Appointment of John Shipsey as Non-Executive Director
Dechra is pleased to announce that, with effect from 1 June
2022, John Shipsey will be appointed as a Non-Executive Director of
the Company. John will be a member of the Group's Audit,
Remuneration and Nomination Committees with the intention that he
will be appointed as Chair of the Audit Committee upon Julian
Heslop's retirement as Audit Committee Chairman on 1 September
2022.
John has valuable experience leading innovative, high growth
companies and brings a wealth of financial and commercial
experience to the business. In addition, his recent tenure as Chief
Financial Officer at FTSE100 Smiths Group PLC (January 2018 to
April 2022) will be a highly relevant asset to the Board and
Dechra. Prior to this he was Chief Financial Officer for Dyson, the
diversified global technology company where he was part of the team
that led its international growth, particularly in Asia. His
previous experience includes a number of senior finance and
strategy roles over 13 years at Diageo plc, including Finance
Director for its Iberia region and Chief Financial Officer of
Schieffelin & Somerset, a US joint venture between Diageo and
LVMH.
John is a Chartered Accountant and has an MBA from INSEAD.
There are no other disclosures to be made in respect of John
Shipsey, pursuant to Listing Rule 9.6.13R.
Enquiries to:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer
Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director
Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABDLFFLELBBBL
(END) Dow Jones Newswires
May 17, 2022 14:06 ET (18:06 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024